Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445877 in Advanced Gastric or Gastroesophageal Junction Cancer
NCT07692204Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SAR445877 in gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by Sanofi. Primary endpoint: Objective Response Rate. Started Jul 2026; status: recruiting.
02
Drugs
SAR445877
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07692204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692204.